



STAFF REPORT

# **Pulmonary Drug Delivery Systems:** *Technologies and Global Markets*

May 2018

***BCC Research Staff***

Report Code: HLC094C

# Table of Contents

<b>Chapter 1: Introduction</b> .....	<b>1</b>
Study Goals and Objectives .....	1
Reasons for Doing This Study .....	1
Scope of Report .....	2
Information Sources .....	2
Methodology .....	2
Geographic Breakdown .....	3
Analyst's Credentials .....	7
Related BCC Research Reports .....	7
<b>Chapter 2: Summary and Highlights</b> .....	<b>9</b>
<b>Chapter 3: Market Dynamics and Technology Background</b> .....	<b>13</b>
Market Definition and Overview .....	13
Mechanism of Action .....	13
Advantages .....	14
Limitations/Challenges .....	14
Pulmonary Conditions and Therapies .....	15
Introduction to the Respiratory System .....	15
Market Driving Factors and Trends .....	16
Improved Patient Compliance and Ease of Use Leading to Adoption of Inhalation Products .....	16
Cost Pressure on Countries Imposing Adoption of Cost-Effective Devices .....	18
Rising Incidence of Asthma and COPD in Developing and Developed Regions .....	19
Market Restraints .....	20
Competition from Generics on the Rise Due to Patent Expiry of Blockbuster Products .....	20
Market Opportunities .....	22
Introduction of Smart Nebulizers .....	22
Regulation and Legislation .....	23
United States .....	23
<b>Chapter 4: Market Breakdown by Pulmonary Drug Delivery Systems</b> .....	<b>26</b>
Overview of Inhalation Techniques .....	26
Leading Respiratory Products .....	28
Dry Powder Inhalers (DPIs) .....	28
Overview .....	28
Marketed Products .....	29
Market Size and Forecast .....	31
Metered Dose Inhalers (MDI's) .....	32
Overview .....	32
Marketed Products .....	33
Market Size and Forecast .....	34
Nebulizers .....	35
Overview .....	35
Marketed Products Overview by Manufacturer .....	37
Market Size and Forecast .....	38
<b>Chapter 5: Pulmonary Drug Delivery Systems in Use</b> .....	<b>40</b>
Therapeutic Agents Administered via Inhalation .....	40
Steroids .....	40
Bronchodilators .....	42

<b>Chapter 6: Market Breakdown by Disease Area .....</b>	<b>47</b>
Introduction .....	47
Asthma .....	48
Asthma Attack .....	49
Asthma and Obesity .....	49
Mortality.....	49
Disease Classification .....	50
Diagnosis .....	50
Treatment and Therapies .....	51
Market Size and Forecasts.....	52
Chronic Obstructive Pulmonary Disease (COPD) .....	53
Diagnosis .....	54
Treatment and Therapies .....	55
Market Size and Forecast .....	55
Other Diseases .....	56
Market Size and Forecast .....	57
<b>Chapter 7: Market Breakdown by Region .....</b>	<b>60</b>
North America.....	60
U.S.A.....	62
Canada.....	63
Mexico.....	63
Europe .....	64
Germany.....	68
United Kingdom .....	68
France.....	70
Italy .....	71
Spain.....	72
Rest of Europe .....	74
Asia Pacific .....	75
China .....	77
Japan .....	78
India .....	78
South Korea .....	78
Rest of Asia Pacific .....	78
Middle East and Africa.....	79
South America.....	82
<b>Chapter 8: Competitive Landscape and Key Developments .....</b>	<b>88</b>
Leading Players and Market Structure Analysis .....	88
Patent Analysis .....	88
List of Key Patents .....	89
Pipeline Analysis .....	90
Key Developments.....	93
Mergers and Acquisitions.....	93
Development of Innovative Products/Novel Product Launches .....	94
Agreements, Collaborations and Partnerships .....	95
<b>Chapter 9: Company Profiles .....</b>	<b>99</b>
<b>Appendix .....</b>	<b>145</b>
Acronyms .....	145
<b>About BCC Research .....</b>	<b>147</b>

About BCC Research ..... 148  
BCC Membership..... 148  
BCC Custom Research..... 148

# List of Tables

Summary Table A Global Market for Pulmonary Drug Delivery Systems, by Type, Through 2022 (\$ Millions) .....	9
Summary Table B Global Market for Pulmonary Drug Delivery Systems, by Region Through 2022 (\$ Millions) .....	10
Table 1 Global Asthma and COPD Snapshot, 1990-2015 .....	19
Table 2 Key Products Going off-Patent, 2016-2021 .....	21
Table 3 Inhaler Device Characteristics Snapshot .....	26
Table 4 Global Market for Pulmonary Drug, by Delivery System, Through 2022 (\$ Millions) .....	27
Table 5 Global Respiratory Product Sales, 2014-2016 (\$ Millions) .....	28
Table 6 Capsule Based Inhaler Devices .....	29
Table 7 Blister Based Inhaler Devices .....	30
Table 8 Reservoir/Cartridge Based Inhaler Devices .....	31
Table 9 Global Dry Powder Inhaler Market, by Region, Through 2022 (\$ Millions).....	31
Table 10 MDIs, HFA Propellant .....	33
Table 11 MDIs, Anti-Inflammatory Medicine.....	33
Table 12 MDIs, Combination Medicine .....	34
Table 13 Commonly Used MDIs .....	34
Table 14 Global MDI Market, by Region, Through 2022 (\$ Millions) .....	34
Table 15 Comparison of Nebulizers.....	36
Table 16 Marketed Nebulizers by Manufacturer .....	37
Table 17 Global Nebulizer Market, by Region, Through 2022 (\$ Millions).....	38
Table 18 Inhaled Steroids .....	41
Table 19 Inhaled Corticosteroids .....	42
Table 20 Inhaled Corticosteroids, Combination Inhalers .....	42
Table 21 Short-Acting Inhaled Beta-Agonist Bronchodilators .....	43
Table 22 Short-Acting Inhaled Muscarinic Antagonist Combination Bronchodilators .....	43
Table 23 Long-Acting Inhaled LABAs (Long-Acting Beta2 Agonists).....	44
Table 24 Long-Acting Inhaled LAMAs (Long-Acting Muscarinic Antagonists).....	44
Table 25 LABA and LAMA Combinations .....	44
Table 26 Top Asthma/COPD Product Sales, 2015-2017 (\$ Millions).....	48
Table 27 U.S. Asthma Mortality, 2015.....	50
Table 28 U.S. Asthma Prevalence, 2015 .....	51
Table 29 Global Asthma Market, by Region Through 2022 (\$ Millions).....	52
Table 30 Global COPD Market, by Region, Through 2022 (\$ Millions).....	56
Table 31 Global Market for Other Pulmonary Diseases, by Region, Through 2022 (\$ Millions) .....	58
Table 32 Canadian Disease Prevalence, Asthma and COPD, 2012-2014 (Number of Persons).....	63
Table 33 European Self-Reported Asthma, 2014 (% of Population) .....	65
Table 34 European Self-Reported COPD, 2014 (% of Population) .....	65
Table 35 Leading Causes of Death in Australia, 2011-2016.....	79
Table 36 Patent Review, Inhaler, 2013-2018.....	89
Table 37 Sunovion Pharmaceuticals, Inc., SUN-101/ eFlow (Glycopyrrolate), 2017.....	91
Table 38 AstraZeneca plc, (Pearl Therapeutics), Pulmonary Products Pipeline .....	91
Table 39 Teva Pharmaceuticals Industries Ltd., Pulmonary Products Pipeline .....	92
Table 40 Vectura Group plc, Pulmonary Products Pipeline .....	92
Table 41 GlaxoSmithKline plc, Pulmonary Products Pipeline .....	93
Table 42 3M Pharmaceuticals, Inc., Marketed Products, 2016 .....	99
Table 43 3M Pharmaceuticals, Inc., Net Revenue, 2015-2017 (\$ Millions).....	100

Table 44 AstraZeneca plc, Marketed Products, 2016.....	103
Table 45 AstraZeneca plc., Key Developments, 2016.....	104
Table 46 AstraZeneca plc, Net Revenue, 2014-2016 (\$ Millions) .....	105
Table 47 Boehringer Ingelheim GmbH, Marketed Product, 2016.....	107
Table 48 Boehringer Ingelheim GmbH, Net Revenue, 2014-2016 (\$ Millions).....	109
Table 49 Cipla, Inc., Marketed Products, 2016 .....	111
Table 50 Cipla, Inc., Net Revenue, 2015-2017 (\$ Millions) .....	113
Table 51 Dr. Reddy's Laboratories Ltd., Marketed Products, 2016.....	115
Table 52 Dr. Reddy's Laboratories Ltd., Net Revenue, 2015-2017 (\$ Millions) .....	115
Table 53 GlaxoSmithKline plc, Marketed Products, 2016.....	118
Table 54 GlaxoSmithKline plc, Net Revenue, 2014-2016 (\$ Millions) .....	119
Table 55 Koninklijke Philips N.V., Marketed Products, 2016.....	122
Table 56 Lupin Limited, Key Developments .....	123
Table 57 Lupin Limited, Net Revenue, 2015-2017 (\$ Millions).....	123
Table 58 Mylan N.V., Marketed Products, 2016 .....	124
Table 59 Mylan N.V., Key Developments, 2016 .....	124
Table 60 Mylan N.V., Net Revenue, 2015-2017 (\$ Millions).....	125
Table 61 Novartis AG, Marketed Products, 2016.....	127
Table 62 Novartis AG, Key Developments, 2016.....	128
Table 63 Novartis AG, Net Revenue, 2014-2016 (\$ Millions) .....	128
Table 64 Omron Corp., Marketed Products, 2016 .....	131
Table 65 Omron Corp., Net Revenue, 2014-2016 (\$ Millions).....	132
Table 66 Pfizer, Inc., Marketed Products, 2016 .....	135
Table 67 Pfizer, Inc., Net Revenue, 2014-2016 (\$ Millions).....	135
Table 68 Teva Pharmaceutical Industries Ltd., Marketed Products, 2016 .....	138
Table 69 Teva Pharmaceutical Industries Ltd., Net Revenue, 2014-2016 (\$ Millions).....	139
Table 70 Vectura Group plc, Marketed Products, 2016 .....	141
Table 71 Vectura Group plc, Net Revenue, 2015-2017 (\$ Millions).....	142
Table 72 Abbreviations Used in Pulmonary Drug Delivery Systems .....	145

# List of Figures

Summary Figure A Global Market for Pulmonary Drug Delivery Systems, by Type, 2016-2022 (\$ Millions)	10
Summary Figure B Global Market for Pulmonary Drug Delivery Systems, by Region, 2016-2022 (\$ Millions)	11
Figure 1 Estimation of Daily Smoking Patterns, by Region, 2015 (Millions)	18
Figure 2 Global Market for Pulmonary Drug, by Delivery System, 2016-2022 (\$ Millions)	27
Figure 3 Global Dry Powder Inhaler Market, by Region, 2016-2022 (\$ Millions)	32
Figure 4 Global MDI Market, by Region, 2016-2022 (\$ Millions)	35
Figure 5 Global Nebulizer Market, by Region, 2016-2022 (\$ Millions)	38
Figure 6 Non-communicable Disease Mortality Share, by Cause of Death, 2015 (%)	47
Figure 7 Global Asthma Market, 2016-2022 (\$ Millions)	52
Figure 8 Global Asthma Market, by Region, 2016-2022 (\$ Millions)	53
Figure 9 Top 10 Leading Causes of Death in the World, 2015 (Millions)	54
Figure 10 Global COPD Market, 2016-2022 (\$ Millions)	55
Figure 11 Global COPD Market, by Region, 2016-2022 (\$ Millions)	56
Figure 12 Global Market for Other Pulmonary Disease, 2016-2022 (\$ Millions)	57
Figure 13 Global Market for Other Pulmonary Disease, by Region, 2016-2022 (\$ Millions)	58
Figure 14 North American Pulmonary Drug Delivery Systems Market, 2016-2022 (\$ Millions)	60
Figure 15 Impact of Asthma in North America, Annual Mortality Rate, 2016 (Per 100,000 People)	61
Figure 16 Impact of COPD in North America, Annual Mortality Rate, 2016 (Per 100,000 People)	62
Figure 17 Mexican Population Health Issues, Proportional Mortality, 2014 (%)	64
Figure 18 Impact of Asthma in Europe, Annual Mortality Rate, 2016 (Per 100,000 People)	66
Figure 19 Impact of COPD in Europe, Annual Mortality Rate, 2016 (Per 100,000 People)	67
Figure 20 European Pulmonary Drug Delivery Systems Market, 2016-2022 (\$ Millions)	68
Figure 21 United Kingdom Mortality Rates in Males, 2015 (%)	69
Figure 22 United Kingdom Mortality Rate in Females, 2015 (%)	70
Figure 23 Leading Causes of Death in Italy in Percent Change, 2005-2016	71
Figure 24 Spain Mortality Rate in Women, 2014 (%)	72
Figure 25 Spain Mortality Rate in Men, 2014 (%)	73
Figure 26 Leading Causes of Death in Europe, 2015	74
Figure 27 Asia Pacific Pulmonary Drug Delivery Systems Market, 2016-2022 (\$ Millions)	75
Figure 28 Impact of Asthma in Asia, Annual Mortality Rate, 2016 (Per 100,000 People)	76
Figure 29 Impact of COPD in Asia, Annual Mortality Rate, 2016 (Per 100,000 People)	77
Figure 30 Impact of Asthma in Middle East and Africa, Annual Mortality Rate, 2016 (Per 100,000 People)	80
Figure 31 Impact of COPD in Middle East and Africa, Annual Mortality Rate, 2016 (Per 100,000 People)	81
Figure 32 Middle East and African Pulmonary Drug Delivery Systems Market, 2016-2022 (\$ Millions)	82
Figure 33 Impact of Asthma in South America, Annual Mortality Rate, 2016 (Per 100,000 People)	83
Figure 34 Impact of COPD in South America, Annual Mortality Rate, 2016 (Per 100,000 People)	84
Figure 35 Impact of COPD in South America, Annual Mortality Rate, 2016 (Per 100,000 People)	85
Figure 36 South American Pulmonary Drug Delivery Systems Market, 2016-2022 (\$ Millions)	86
Figure 37 3M Pharmaceuticals, Inc., Revenue Share by Region, 2016 (%)	101
Figure 38 3M Pharmaceuticals, Inc., Revenue Share by Business Segment, 2016 (%)	102
Figure 39 AstraZeneca plc, Revenue Share, by Region, 2016 (%)	105
Figure 40 AstraZeneca plc, Revenue Share, by Business Segment, 2016 (%)	106
Figure 41 Boehringer Ingelheim GmbH, Research and Development Expenditure, 2014-2016 (\$ Millions)	108

Figure 42 Boehringer Ingelheim GmbH, Revenue Share by Region, 2016 (%) .....	109
Figure 43 Boehringer Ingelheim GmbH, Revenue Share, by Business Segment, 2016 (%) .....	110
Figure 44 Cipla, Inc. Research and Development Expenditure, 2014-2017 (%).....	112
Figure 45 Cipla, Inc., Revenue Share, by Region, 2017 (%).....	113
Figure 46 Cipla, Inc., Revenue Share, by Business Segment, 2017 (%) .....	114
Figure 47 Dr. Reddy's Laboratories Ltd., Revenue Share, by Region, 2017 (%) .....	116
Figure 48 Dr. Reddy's Laboratories Ltd., Revenue Share, by Business Segment, 2017 (%).....	117
Figure 49 GlaxoSmithKline plc, Pharmaceuticals Revenue Share, by Therapy Areas, 2016 (%) .....	120
Figure 50 GlaxoSmithKline plc, Revenue Share, by Region, 2016 (%).....	121
Figure 51 Mylan N.V., Revenue Share by Therapy Areas, 2016 (%) .....	125
Figure 52 Mylan N.V., Revenue Share, by Region, 2016 (%).....	126
Figure 53 Novartis AG, Revenue Share, by Region, 2016 (%) .....	129
Figure 54 Novartis AG, Revenue Share, by Business Segment, 2016 (%) .....	130
Figure 55 Omron Corp., Revenue Share, by Healthcare Business Segment (HCB), 2017 (%).....	133
Figure 56 Omron Corp., Revenue Share, by Region, 2017 (%).....	134
Figure 57 Pfizer, Inc., Revenue Share, by Region, 2016 (%).....	136
Figure 58 Pfizer, Inc., Revenue Share, by Business Segment, 2016 (%) .....	137
Figure 59 Teva Pharmaceutical Industries Ltd., Revenue Share, by Region, 2017 (%).....	139
Figure 60 Teva Pharmaceutical Industries Ltd., Revenue Share, by Business Segment, 2016 (%) .....	140
Figure 61 Vectura Group plc, Research and Development Expenditure, 2014-2016 (\$ Millions) .....	142
Figure 62 Vectura Group plc, Revenue Share, by Region, 2017 (%).....	143





*About BCC Research*

## *About BCC Research*

With our unparalleled 45-year history, BCC Research provides comprehensive analysis of global market sizing, forecasting and industry intelligence, covering markets where advances in science and technology are improving the quality, standard and sustainability of businesses, economies and lives.

## *BCC Membership*

From market sizing and forecasts, to opportunity assessments and competitive analyses, our ever-expanding library gives you the data, insights and intelligence required to ensure your project is a success. Members benefit from ongoing, unlimited access to the category or collections of their choice, and most membership packages pay for themselves within two to three reports being accessed.

Did you buy this report? You may qualify to apply your purchase price towards a full membership. Call 866-285-7215 or email [info@bccresearch.com](mailto:info@bccresearch.com) to request a demo.

## *BCC Custom Research*

Our experts provide custom research projects to those working to identify new markets, introduce new products, validate existing market share, analyze competition and assess the potential for products to impact existing markets. With impressive academic credentials and broad and deep knowledge of global industrial markets, our independent analysts and consultants develop the facts, figures, analysis and assessments to inform the decisions that will move your company ahead. Confidential inquiries to: [custom@bccresearch.com](mailto:custom@bccresearch.com) or 781-205-2429.

## DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and is of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it be considered as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is speculative in nature. BCC Research and the author assume no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

ISBN: 978-1-62296-722-3  
May 2018